Previous 10 | Next 10 |
2023-08-23 08:47:02 ET VCI Global ( VCIG ) +61% after announces visionary collaboration with Microsoft Azure OpenAI . iTeos Therapeutics ( ITOS ) +37% in reaction as Roche send anti-TIGIT developers higher after mistakenly-released cancer drug data . Arcus ...
2023-08-23 07:31:22 ET More on Roche Roche drives rival anti-TIGIT developers higher after cancer drug data Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender Roche, Alnylam in pact for blood pressure candidate Roivant report...
2023-08-08 08:02:19 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q2 GAAP EPS of -$0.96. The company’s cash, cash equivalents, and investments position was $677.5 million as of June 30, 2023, as compared to $791.9 million as of June 30, 2022. For furth...
– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated enrollment in Phase 1 trial of EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway &...
2023-07-10 04:56:16 ET Summary The new July 2023 selections are the current top positive/negative forensic stocks based on combined scores from four different forensic algorithms. Both the 2022 January Positive Forensic portfolio beat the S&P 500 by +6.59% and the Negative For...
2023-06-08 12:15:22 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle aga...
2023-06-04 10:04:13 ET Summary Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary compounds in its pipeline and has a potentially lucrative partnership with GlaxoSmithKline. The ...
2023-05-10 08:58:59 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q1 GAAP EPS of -$0.44. The company’s cash, cash equivalents, and investments position was $706.6 million as of March 31, 2023, as compared to $824.0 million as of March 31, 2022. Research ...
– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine pathway, EOS-984, is expected to enter cli...
- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a first-in-class program targeting a new mechanism of action in the a...
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
iTeos Therapeutics Inc. Website:
2024-05-22 01:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 07:00:04 ET Swayampakula Ramakanth from H.C. Wainwright issued a price target of $46.00 for ITOS on 2024-05-13 06:11:00. The adjusted price target was set to $46.00. At the time of the announcement, ITOS was trading at $17.44. ITOS currently trades -32.51% ver...
A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 98.7% to $8.88 on volume of 168,692,127 shares AEye Inc. (LIDR) rose 115.0% to $2.58 on volume of 156,236,079 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 17.3% to $0.7609 on volume of 123,678,040 s...